A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.
Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.
Failure is very profitable for Pain Therapeutics CEO Remi Barbier.
Using Northwest Bio as an example, I'm going to teach you how to read clinical trial data to find red flags and bad stuff biotechs don't want you to see.
An Alzheimer's drug under development by Danish pharma Lundbeck failed a pivotal phase III study and Axovant suffered collateral damage.
When an experimental glaucoma drug is only marginally effective, one way to produce positive clinical trial results is to enroll patients with borderline glaucoma.
TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.
Sarepta, its shareholders, biotech investors, and Duchenne patients and their families have been waiting years for today's news.
Sarepta's largest shareholder talks about the company's future following FDA approval of its Duchenne muscular dystrophy drug.
The FDA told Spectrum not to seek approval for its bladder cancer drug. Spectrum filed anyway but never told investors about the FDA warning.
Collectively, the data will give investors a clearer measure of Gilead's internal drug development efforts outside of its core hepatitis C and HIV strengths.
The departure of an important eteplirsen critic from the FDA could be a sign that the internal agency debate over Sarepta's drug is coming to an end.
How will biotech stocks end the year? Will FDA approve Sarepta's drug? Will Gilead finally buy another company?
Important clinical trial results in Alzheimer's, cancer and Crohn's disease and a big FDA decision for Sarepta are expected before the end of the year.
Bluebird Bio removed a significant concern investors had about its gene therapy manufacturing process, sending shares higher Thursday.
Retrophin announced positive results from a study in which patients with a rare kidney disease responded to treatment with its experimental drug sparsentan.
Celgene owns the rights to the Agios drug known as AG-221 under an existing partnership.
CEO Brent Saunders said Allergan will act differently, pledging to limit price increases on drugs the company sells as part of a 'commitment to innovation, access and responsible pricing ideals.'
Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.
GED-0301 is one of three drugs -- Otezla and ozanimod are the others -- which form the core of Celgene's burgeoning immunology and inflammation franchise.
Investors once OK with waiting patiently for a Gilead rebound are growing frustrated, even angry, at the company's lack of progress.
The 18% response rate for fostamatinib in the Rigel phase III study was on the lower end of investor expectations.
The drugmaker says it will launch the product in 'several weeks' at a list price of $300 per two-park carton.